Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 EUR | +1.24% | -1.90% | -44.87% |
04-04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
04-03 | AB Science: reconsideration possible for masitinib in ALS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.87% | 107M | |
+4.06% | 69.85B | |
+11.81% | 8.98B | |
-14.44% | 4.89B | |
+41.60% | 4.44B | |
+5.96% | 3.95B | |
+23.46% | 2.49B | |
-19.32% | 2.4B | |
-27.04% | 2.28B | |
+7.97% | 1.96B |
- Stock Market
- Equities
- AB Stock
- News AB Science
- AB Science Gets Health Canada's Screening Acceptance For Amyotrophic Lateral Sclerosis Therapy